Tenaya–Alnylam $1.13B Deal Targets Heart Disease Genes
South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
South San Francisco, California — March 5, 2026 Tenaya Therapeutics and Alnylam Pharmaceuticals have announced a major research collaboration...
King of Prussia, Pennsylvania | December 23, 2025 — Phio Pharmaceuticals Corp. announced a significant advancement in its drug...
